- Home
- AGEN vs SNBR Comparison
AGEN vs SNBR Comparison
Compare AGEN & SNBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- SNBR
- Stock Information
- Founded
- AGEN 1994
- SNBR 1987
- Country
- AGEN United States
- SNBR United States
- Employees
- AGEN N/A
- SNBR N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- SNBR Home Furnishings
- Sector
- AGEN Health Care
- SNBR Consumer Discretionary
- Exchange
- AGEN Nasdaq
- SNBR Nasdaq
- Market Cap
- AGEN 142.8M
- SNBR 161.7M
- IPO Year
- AGEN 2000
- SNBR 1998
- Fundamental
- Price
- AGEN $4.25
- SNBR $6.19
- Analyst Decision
- AGEN Buy
- SNBR Hold
- Analyst Count
- AGEN 2
- SNBR 2
- Target Price
- AGEN $14.50
- SNBR $9.00
- AVG Volume (30 Days)
- AGEN 431.2K
- SNBR 398.1K
- Earning Date
- AGEN 11-11-2025
- SNBR 10-29-2025
- Dividend Yield
- AGEN N/A
- SNBR N/A
- EPS Growth
- AGEN N/A
- SNBR N/A
- EPS
- AGEN N/A
- SNBR N/A
- Revenue
- AGEN $101,706,000.00
- SNBR $1,524,620,000.00
- Revenue This Year
- AGEN $60.49
- SNBR N/A
- Revenue Next Year
- AGEN N/A
- SNBR $0.88
- P/E Ratio
- AGEN N/A
- SNBR N/A
- Revenue Growth
- AGEN N/A
- SNBR N/A
- 52 Week Low
- AGEN $1.38
- SNBR $4.48
- 52 Week High
- AGEN $7.34
- SNBR $20.73
- Technical
- Relative Strength Index (RSI)
- AGEN 45.64
- SNBR 26.57
- Support Level
- AGEN $3.78
- SNBR $6.10
- Resistance Level
- AGEN $4.38
- SNBR $7.39
- Average True Range (ATR)
- AGEN 0.24
- SNBR 0.43
- MACD
- AGEN 0.00
- SNBR -0.10
- Stochastic Oscillator
- AGEN 47.55
- SNBR 3.35
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About SNBR Sleep Number Corporation
Sleep Number Corp. is a wellness technology company engaged in the design, manufacturing, marketing and distribution of sleep solutions. The Company generates revenue by marketing and selling its smart beds directly to new and existing customers through its vertically integrated, exclusive, direct-to-consumer retail touch points including Stores, Online, Phone, and Chat (Total Retail). The products offered by the company are Mattresses, Bedding, Pillows and Furniture.